SC 13G
Amended Statement of Ownership
AN2 Therapeutics, Inc. Filed Acc 0000921895-22-001065
Stakes reported in this filing
Stake history · largest stake in each 13D and 13G
- 2026-11-13 SCHEDULE 13G/A · Eric Easom 6.2%
- 2026-11-13 SCHEDULE 13G/A · Coastlands Capital LP 9.99%
- 2025-06-18 SCHEDULE 13D/A · BML Investment Partners, L.P. 1.4%
- 2025-05-30 SCHEDULE 13D/A · BML Investment Partners, L.P. 10.7%
- 2025-05-07 SCHEDULE 13D · BML Investment Partners, L.P. 19.1%
- 2024-11-14 SC 13G/A · Citadel Advisors LLC 0.0%
- 2024-11-14 SC 13G/A · Biotechnology Value Fund, L.P. 0%
- 2024-11-13 SC 13G/A · TCG Crossover GP I, LLC 5.2%
- 2024-08-28 SC 13G/A · Octagon Capital Advisors LP 0%
- 2024-08-14 SC 13G/A · BML Investment Partners, L.P. 19.3%
- 2024-08-13 SC 13G/A · RA Capital Management, L.P. 6.7%
- 2024-08-12 SC 13G · BML Investment Partners, L.P. 14.2%
- 2024-07-03 SC 13G · Octagon Capital Advisors LP 10.1%
- 2024-04-10 SC 13G · James N. Topper 5.0%
- 2024-02-14 SC 13G/A · RA Capital Management, L.P. 18.7%
Loading sc13g07422antx_04042022.htm…